Adult Acute Myeloblastic Leukemia Without Maturation (M1) Completed Phase 1 Trials for Tanespimycin (DB05134)

IndicationStatusPhase
DBCOND0028523 (Adult Acute Myeloblastic Leukemia Without Maturation (M1))Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00098423Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic SyndromesTreatment